Lars Ny - Concepedia

Author

Lars Ny

Sahlgrenska University Hospital ORCID

Also Known As

Kristell Le Gal, L Ny, L. NY, L. Ny, LARS NY, Lars Ny, Ny, Lars, van Akkooi, Alexander C. J.

268

Publications

4.7K

Citations

H-Index

118

Concepts

All Affiliations

Sahlgrenska University Hospital University of Gothenburg Lund University Karolinska University Hospital Skåne University Hospital

About

Lars Ny is an author at Sahlgrenska University Hospital specializing in medicine, physiology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	1.4K
2	Social Sciences	5	5	177
3	Health Sciences	4	4	171
4	Education	1	1	45
5	Natural Sciences	1	1	68

Lars Ny

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Paolo A. Ascierto, Georgina V. Long, Caroline Robert, JAMA Oncology	2018	330
Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types Nils Johan Fredriksson, Lars Ny, Jonas A. Nilsson, Nature Genetics Somatic VariantSomatic MutationsTumor HeterogeneityGeneticsSystematic Analysis	2014	302
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma Caroline Robert, Georgina V. Long, Benjamin Brady, Journal of Clinical Oncology	2020	208
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma Lars Ny, Henrik Jespersen, Joakim Karlsson, Nature Communications	2021	170
Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model Henrik Jespersen, Mattias F. Lindberg, Marco Donia, Nature Communications T-regulatory CellImmunologyAdoptive Cell TransferImmune Cell TherapyT Cells	2017	163
Molecular profiling of driver events in metastatic uveal melanoma Joakim Karlsson, Lisa M. Nilsson, Suman Mitra, Nature Communications	2020	162
Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain Anne Lund Krarup, Lars Ny, Jenny Gunnarsson, Scandinavian Journal of Gastroenterology	2013	153
Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain Anne Lund Krarup, Lars Ny, Magnus Åstrand, Alimentary Pharmacology & Therapeutics	2011	130
HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice Elin M.V. Forsberg, Mattias F. Lindberg, Henrik Jespersen, Cancer Research	2019	126
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination Ana Arance, Luis de la Cruz‐Merino, Teresa M. Petrella, Journal of Clinical Oncology	2022	124

Page 1